Mark E. Dunlap, MD - Department of Physiology and Biophysics

More documents

Recommendations

Info

Mark E. Dunlap, MDCurriculum Vitae, page 8"Modulation of Ganglion Transmission in Heart Failure "; 30% effort2012-2019 NIH Heart Failure Network, HL110336-01 - $2,500,000Co-PI, 5% effort, Cleveland Center, project entitled:“Renal Sympathetic Denervation in Congestive Heart Failure”; Wilson Tang, MD, PI(B) Clinical Trials1990-1996 Cooperative Studies Program #995Jointly sponsored by NIH and Department of Veterans AffairsSite PI, "Trial to evaluate the effect of digitalis on mortality in heart failure — DIG”1995-1996 Bristol-Myers Squibb, Pharmaceutical Research InstituteSite PI, "Multicenter, randomized evaluation of the acute and long-term hemodynamiceffects and safety of the angiotensin II receptor antagonist irbesartan in the treatment ofheart failure"1995-1996 Otsuka America Pharmaceutical, Inc.Site PI, "A randomized, double-blind, placebo controlled, multiple dose study of the chronicadministration of vesnarinone in heart failure — VEST"1996-2004 NIHLBI; Site PI, "Prevention of Events with Angiotensin Converting Enzyme Inhibition —PEACE" (also on Steering Committee for this study)1997-1998 Bristol-Myers Squibb, Pharmaceutical Research InstituteSite PI, "Multicenter, Randomized Study of the Long-term Hemodynamic Effects and Safetyof the Dual Metalloprotease Inhibitor (DMP-i)”1996-2000 Astra USA, Inc.; Site PI, "Metoprolol Randomized Intervention Trial in Congestive HeartFailure - MERIT-HF"1997-1998 Bristol-Myers Squibb, Pharmaceutical Research InstituteSite PI, "Inhibition of Metallo Protease by BMS-186716 (Omapatrilat) in a RandomizedExercise and Symptoms Study in Subjects with Heart Failure: The IMPRESS Trial” (also aRegional Coordinator for this study)1998-1999 Bristol-Myers Squibb, Pharmaceutical Research InstituteSite PI, “A Multicenter, Randomized, Double Blind, Lisinopril and Placebo Controlled Trial ofthe Antihypertensive Efficacy and Safety of Omapatrilat in Black Subjects with Mild toModerate Hypertension"1998-1999 Astra Pharmaceuticals, LP; Site PI, “Evaluation of the Tolerability and Safety ofCandesartan Cilexetil in Patients with Congestive Heart Failure: A Multicenter, Double-blind,Placebo-controlled, Randomized, Forced Dose-Titration Study”1998-2003 Astra-ZenecaSite PI, “Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality andMorbidity -CHARM” (also a U.S. National Leader and Steering Committee Member for thisstudy, and Vice-Chair of the U.S. Investigative Committee)1999-2002 Bristol-Myers Squibb, Site PI: “Omapatrilat Vs. Enalapril Randomized Trial of Utility inReducing Events — OVERTURE”2000-2001 CV Therapeutics; Site PI, “Safety and efficacy of Ranolazine in heart failure”2001-2002 University of MissouriSite PI, “Interpreting the Kansas City Cardiomyopathy Questionnaire (KCCQ)”2000-2003 Department of Veterans Affairs CSP #442:Site PI, “Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH)”2001-2004 MIMC, NitroMed
Mark E. Dunlap, MDCurriculum Vitae, page 9Site PI, “African-American Heart Failure Trial — A-HeFT”2003-2006 Department of Veterans Affairs CSP #526Site PI, “Thyroid Hormone Analog: Treatment of Heart Failure (DITPA)”2005-2006 Otsuka Maryland Research Institute, Inc., Site PI: “Multi-center, Randomized, Double-blind,Placebo-controlled Study to Evaluate the Effect of Single Oral Tolvaptan Tablets onHemodynamic Parameters in Subjects with HF--ECLIPSE”2006-presentAmgen, Inc.: “A Double-blind, Randomized, Placebo-controlled, Multicenter Study toAssess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity inHeart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction andAnemia: RED-HF Trial — Reduction of Events with Darbepoetin alfa in Heart Failure Trial”;Site co-PI and member, Steering Committee and US National Leadership2007-2009 Merck & Co., Inc.; Site PI, “Placebo-controlled Randomized study of the selective A1adenosine receptor antagonist KW-3902 for patients hospitalized with acute HF and volumeOverload to assess Treatment Effect on CongesTion and renal function — PROTECT”2007-2011 Johnson and Johnson: “Double-Blind, Placebo-Controlled, Multicenter Acute Study ofClinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure —ASCEND-HF”; Site PI and member, Steering Committee2008-2010 Cardiokine Biopharma, LLC; Site PI, “Treatment of HyponatrEmia BAsed on LixivAptan inNYHA Class III/IV Cardiac Patient Evaluation — THE BALANCE Study”2007-present2010-present2010-present2010-present2011-present2011-presentNIHLBI; Site PI, “Treatment Of Preserved Cardiac function heart failure with an AldosteroneanTagonist — TOPCAT”A Multi-Centre, Randomized Study to Assess the Effects of Adaptive Servo Ventilation(ASV) on Survival and Frequency of Cardiovascular (CV) Hospital Admissions in Patientswith Heart Failure (HF) and Sleep Apnea (SA) – The ADVENT-HF Trial, site PISponsor: Canadian Institutes for Health Research (CIHR) and Philips-Respironics Inc.Hyponatremia Registry, site PISponsor: Otsuka PharmaceuticalsINcrease Of VAgal TonE in chronic Heart Failure: INOVATE HF, site PISponsor: BioControl Medical, Inc.Symptoms And Length of stay After sodium Correction in Inpatient Adults:Tolvaptan versus Fluid Restriction (SALACIA) study, site PISponsor: Otsuka PharmaceuticalsA Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safetyand Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With LeftVentricular Systolic Dysfunction Hospitalized for Acute Heart Failure: Amgen 423, site PISponsor: Amgen, Inc.(C)Co-Principal Investigator1989-1994 NIH RO1 (Marc D. Thames, MD, PI)"Cardiac Receptor with Vagal C-Fiber Afferents"--$810,2371991-1995 Merit Review (Marc D. Thames, MD, PI)"Reflex Control in Congestive Heart Failure"Department of Veterans Affairs--$653,100
Page 1 and 2: CURRICULUM VITAEMark Evans Dunlap,
Page 3 and 4: Mark E. Dunlap, MDCurriculum Vitae,
Page 5: Mark E. Dunlap, MDCurriculum Vitae,

Mark E. Dunlap, MD - Department of Physiology and Biophysics

Create successful ePaper yourself

Delete template?

Save as template?